One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Immunotherapy for Hematologic Malignancies
Charles Craddock, MD1,2 and Jonathan W. Friedberg, MD3
doi : 10.1200/JCO.20.03106
Journal of Clinical Oncology 39, no. 5 (February 10, 2021) 343-345.
Biology in Practice: Harnessing the Curative Potential of the Immune System in Lymphoid Cancers
Tomohiro Aoki, MD, PhD1,2; Kerry J. Savage, MD1,3; and Christian Steidl, MD1,2
doi : 10.1200/JCO.20.01761
Journal of Clinical Oncology 39, no. 5 (February 10, 2021) 346-360.
Graft Versus Leukemia: Current Status and Future Perspectives
Aideen T. O'Neill, MBBS, MRCP, FRCPath1 and Ronjon Chakraverty, MBChB, MRCP, FRCPath, PhD1
doi : 10.1200/JCO.20.01801
Journal of Clinical Oncology 39, no. 5 (February 10, 2021) 361-372.
Optimizing Donor Choice and GVHD Prophylaxis in Allogeneic Hematopoietic Cell Transplantation
Shernan G. Holtan, MD1; Jurjen Versluis, MD2; Daniel J. Weisdorf, MD1; and Jan J. Cornelissen, MD, PhD2
doi : 10.1200/JCO.20.01771
Journal of Clinical Oncology 39, no. 5 (February 10, 2021) 373-385.
Biology of Disease Relapse in Myeloid Disease: Implication for Strategies to Prevent and Treat Disease Relapse After Stem-Cell Transplantation
Joseph C. Rimando, MD1; Matthew J. Christopher, MD, PhD1; Michael P. Rettig, PhD1; and John F. DiPersio, MD, PhD1
doi : 10.1200/JCO.20.01587
Journal of Clinical Oncology 39, no. 5 (February 10, 2021) 386-396.
Defining the Role of Donor Lymphocyte Infusion in High-Risk Hematologic Malignancies
Christoph Schmid, MD1; Jürgen Kuball, MD2; and Gesine Bug, MD3
doi : 10.1200/JCO.20.01719
Journal of Clinical Oncology 39, no. 5 (February 10, 2021) 397-418.
Immune Biology of Acute Myeloid Leukemia: Implications for Immunotherapy
Sophia Khaldoyanidi, MD, PhD1; Dirk Nagorsen, MD, PhD1; Anthony Stein, MD2; Gerrit Ossenkoppele, PhD, MD3; and Marion Subklewe , MD, PhD4
doi : 10.1200/JCO.20.00475
Journal of Clinical Oncology 39, no. 5 (February 10, 2021) 419-432.
Vaccination as Immunotherapy in Hematologic Malignancies
Jessica Liegel, MD1; Matthew Weinstock, MD1; Jacalyn Rosenblatt, MD1; and David Avigan, MD1
doi : 10.1200/JCO.20.01706
Journal of Clinical Oncology 39, no. 5 (February 10, 2021) 433-443.
Immunotherapy of Acute Lymphoblastic Leukemia and Lymphoma With T Cell–Redirected Bispecific Antibodies
Federico Lussana , MD, PhD1; Giuseppe Gritti , MD, PhD1; and Alessandro Rambaldi , MD1,2
doi : 10.1200/JCO.20.01564
Journal of Clinical Oncology 39, no. 5 (February 10, 2021) 444-455.
How I Manage: Pathophysiology and Management of Toxicity of Chimeric Antigen Receptor T-Cell Therapies
Patrick M. Reagan, MD1 and Sattva S. Neelapu, MD2
doi : 10.1200/JCO.20.01616
Journal of Clinical Oncology 39, no. 5 (February 10, 2021) 456-466.
Autologous Stem Cell Transplantation in the Management of Relapsed Non-Hodgkin Lymphoma
Alvaro J. Alencar, MD1 and Craig H. Moskowitz, MD1
doi : 10.1200/JCO.20.01751
Journal of Clinical Oncology 39, no. 5 (February 10, 2021) 467-475.
Chimeric Antigen Receptor T-Cell Therapy in the Management of Relapsed Non-Hodgkin Lymphoma
Krishna V. Komanduri, MD1
doi : 10.1200/JCO.20.01749
Journal of Clinical Oncology 39, no. 5 (February 10, 2021) 476-486.
Is There Still a Role for Allogeneic Transplantation in the Management of Lymphoma?
Nirav N. Shah, MD, MS1 and Mehdi Hamadani, MD1,2
doi : 10.1200/JCO.20.01447
Journal of Clinical Oncology 39, no. 5 (February 10, 2021) 487-498.
Extending the Promise of Chimeric Antigen Receptor T-Cell Therapy Beyond Targeting CD19+ Tumors
Natalie S. Grover, MD1,2; Nicholas Tschernia, MD1,2; Gianpietro Dotti, MD1,3; and Barbara Savoldo, MD, PhD1,4
doi : 10.1200/JCO.20.01738
Journal of Clinical Oncology 39, no. 5 (February 10, 2021) 499-513.
Adoptive T-Cell Therapy for Epstein-Barr Virus–Related Lymphomas
Helen E. Heslop, MD1; Sandhya Sharma, BS1; and Cliona M. Rooney, PhD1
doi : 10.1200/JCO.20.01709
Journal of Clinical Oncology 39, no. 5 (February 10, 2021) 514-524.
Checkpoint Blockade in Lymphoma
Stephen M. Ansell, MD, PhD1
doi : 10.1200/JCO.20.01522
Journal of Clinical Oncology 39, no. 5 (February 10, 2021) 525-533.
Building a Fit for Purpose Clinical Trials Infrastructure to Accelerate the Assessment of Novel Hematopoietic Cell Transplantation Strategies and Cellular Immunotherapies
Steven M. Devine, MD1,2; and Mary M. Horowitz, MD, MS3,4
doi : 10.1200/JCO.20.01623
Journal of Clinical Oncology 39, no. 5 (February 10, 2021) 534-544.
